<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report two cases of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (SMDS) which followed successful treatment of a primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> with high-dose chemotherapy supported by reinfusion of autologous stem cells </plain></SENT>
<SENT sid="1" pm="."><plain>The SMDS was diagnosed 24 months and 40 months, respectively, following autografting </plain></SENT>
<SENT sid="2" pm="."><plain>Both patients lived for 7 months after the diagnosis of SMDS </plain></SENT>
<SENT sid="3" pm="."><plain>Our cases support the view that there is an increased risk of SMDS/<z:hpo ids='HP_0002488'>acute leukemia</z:hpo> following autologous marrow transplantation </plain></SENT>
</text></document>